Universities of Birmingham and Warwick form spinout company, 4D Biomaterials has been awarded funding by Innovate UK to develop and commercialise a new class of liquid resins that can be custom-printed into bioresorbable 3D tissue scaffolds.
These tissue scaffolds improve wound healing following major surgery.
4D Biomaterials was formed as a spinout by University of Birmingham Enterprise and Warwick Innovations. The company is developing its new polycarbonate-based resins which are the result of a major programme of biomaterials research and tissue engineering led by Professor Andrew Dove at Birmingham and previously Warwick Universities.
Having recently established a self-contained independent laboratory and office space in MediCity on the world-renowned Boots site in Nottingham, 4D Biomaterials has made several senior appointments to advance its product development and operational capabilities.
The new head of R&D Operations is Dr Andrew Naylor, an experienced industrial chemist whose career to date has spanned polymer and pharmaceutical process and product development, and has included a leading role in the set-up of an MHRA licensed manufacturing facility compliant within good manufacturing practice guidelines. Dr Naylor will build operational capacity for the company, including capabilities for resin and device production, and testing and characterisation of resins and 3D printed parts.
Dr Naylor will be working with Product Development Chemist Dr Siobhan Kilbride, who recently completed her PhD with Professor Andrew Dove at the University of Birmingham, and has first-hand experience of producing the resins in Birmingham’s laboratories.
Complementing the operational and laboratory based teams, 4D Biomaterials is now also working with consultant Dr Phil Reeves, who is a highly experienced 3D printing technologist and strategist, having worked with some of the leading global companies on additive manufacturing in the medical device sector.
CEO Philip Smith said: “Thanks to Innovate UK, we have been able to establish a fully-equipped laboratory at MediCity in which we will develop our product range and scale-up manufacture in preparation for a comprehensive pre-clinical testing programme. Andrew, Siobhan and Phil have brought a highly valuable mix of experience and talent to the team and have already made good progress in scaling production of the resins and developing designs for our first range of 3D printed medical devices.”
The company has also made solid progress on the commercial front securing a first letter of intent from a potential customer in the US and a very encouraging response to independent market research covering three potential medical device applications. Smith added: “We are now approaching potential investors with the aim of raising a further £1m to fund the next stage of product development and pre-clinical testing.”